Schonfeld Strategic Advisors LLC purchased a new position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 724,319 shares of the company's stock, valued at approximately $5,845,000. Schonfeld Strategic Advisors LLC owned approximately 1.03% of ORIC Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Diadema Partners LP bought a new position in shares of ORIC Pharmaceuticals during the fourth quarter worth about $1,729,000. Franklin Resources Inc. increased its position in shares of ORIC Pharmaceuticals by 26.1% during the third quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock valued at $9,067,000 after acquiring an additional 196,804 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in ORIC Pharmaceuticals by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,295,025 shares of the company's stock valued at $10,452,000 after acquiring an additional 180,140 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ORIC Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock worth $5,788,000 after acquiring an additional 103,237 shares during the period. Finally, Natixis purchased a new stake in shares of ORIC Pharmaceuticals in the fourth quarter worth $645,000. 95.05% of the stock is currently owned by institutional investors and hedge funds.
ORIC Pharmaceuticals Stock Performance
NASDAQ ORIC traded up $0.70 during trading hours on Thursday, reaching $5.40. The company's stock had a trading volume of 182,354 shares, compared to its average volume of 640,301. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock has a market cap of $383.86 million, a PE ratio of -2.95 and a beta of 1.37. The company's 50-day moving average is $5.99 and its two-hundred day moving average is $8.12.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.09. Equities analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently commented on ORIC shares. Guggenheim reaffirmed a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday. Oppenheimer cut their price target on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, ORIC Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $19.17.
View Our Latest Analysis on ORIC Pharmaceuticals
About ORIC Pharmaceuticals
(
Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Articles
Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
